25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.

      American Journal of Physiology - Heart and Circulatory Physiology

      Animals, Diabetes Mellitus, Type 2, blood, drug therapy, genetics, Diabetic Cardiomyopathies, physiopathology, ultrasonography, Diet, High-Fat, Disease Models, Animal, Dyslipidemias, Echocardiography, Doppler, Fibrosis, Glutathione Peroxidase, metabolism, Hypertrophy, Left Ventricular, Hypoglycemic Agents, administration & dosage, pharmacology, Inflammation Mediators, Infusions, Subcutaneous, Insulin Resistance, Intercellular Adhesion Molecule-1, Lipid Metabolism, drug effects, Macrophage Colony-Stimulating Factor, Male, Mice, Mitochondria, Heart, pathology, Myocardium, NADPH Oxidase, Oxidative Stress, Peptides, Receptors, Glucagon, agonists, Superoxide Dismutase, Time Factors, Venoms, Ventricular Dysfunction, Left, Ventricular Function, Left, Ventricular Remodeling

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is a remedy for type 2 diabetes mellitus (T2DM). Ex-4 ameliorates cardiac dysfunction induced by myocardial infarction in preclinical and clinical settings. However, it remains unclear whether Ex-4 may modulate diabetic cardiomyopathy. We tested the impact of Ex-4 on two types of diabetic cardiomyopathy models, genetic (KK) and acquired T2DM induced by high-fat diet [diet-induced obesity (DIO)], to clarify whether Ex-4 may combat independently of etiology. Each type of mice was divided into Ex-4 (24 nmol·kg(-1)·day(-1) for 40 days; KK-ex4 and DIO-ex4) and vehicle (KK-v and DIO-v) groups. Ex-4 ameliorated systemic and cardiac insulin resistance and dyslipidemia in both T2DM models. T2DM mice exhibited systolic (DIO-v) and diastolic (DIO-v and KK-v) left ventricular dysfunctions, which were restored by Ex-4 with reduction in left ventricular hypertrophy. DIO-v and KK-v exhibited increased myocardial fibrosis and steatosis (lipid accumulation), in which were observed cardiac mitochondrial remodeling and enhanced mitochondrial oxidative damage. Ex-4 treatment reversed these cardiac remodeling and oxidative stress. Cytokine array revealed that Ex-4-sensitive inflammatory cytokines were ICAM-1 and macrophage colony-stimulating factor. Ex-4 ameliorated myocardial oxidative stress via suppression of NADPH oxidase 4 with concomitant elevation of antioxidants (SOD-1 and glutathione peroxidase). In conclusion, GLP-1R agonism reverses cardiac remodeling and dysfunction observed in T2DM via normalizing imbalance of lipid metabolism and related inflammation/oxidative stress.

          Related collections

          Author and article information

          Journal
          23709595
          10.1152/ajpheart.00990.2012

          Comments

          Comment on this article